Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/89—Polysiloxanes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/89—Polysiloxanes
  • A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/0208—Tissues; Wipes; Patches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
  • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms

Definitions

• the present invention relates to a silicone material for the release of an active molecule incorporated therein.
• the invention aims in particular the release of active molecules useful in the pharmaceutical, cosmetic and personal care.
• Silicone patches have been described. These descriptions specify that they are formed by an adhesive silicone gel film, enclosing the active molecule. Silicone gels are biocompatible adhesives that are not aggressive to the skin.
• the patent FR 2,618,337 describes a surgical dressing comprising a layer of silicone gel associated with a laminated silicone elastomer film. Gel and elastomer formulations are polyaddition formulations.
• the dressing may include active molecules.
• Patent FR 2,735,024 also describes a silicone patch.
• the gel can theoretically contain from 0.01 to 30% of active molecule. The contents are however limited to a few% in the examples. It is also known that the gels consist of polydimethylsiloxane linkages linked together by Si (CH 3 ) 2 -CH 2 -CH 2 -Si (CH 3 ) 2 - bridges; as is the case in this document, have very limited solvent powers, which necessarily limits the content of active molecule that can be incorporated.
• the gel described in this patent may also contain a cutaneous transfer promoter intended, as its name suggests, to accelerate the passage of active molecules whose diffusion is low. It also mentions the possible presence of a solvent, such as ethylene glycol monoethyl ether, which is known to promote tissue penetration.
• Another object of the invention is to provide such a material which is adhesive.
• the subject of the invention is therefore a silicone material, preferably an adhesive material, for the release of an active molecule intended for cosmetic use or in the personal care or of a pharmaceutically or biologically active molecule for pharmaceutical use, which is formed a silicone material, preferably an adhesive material, in which said molecule is incorporated and a compatibilizing agent in which said active molecule is soluble, said compatibilizing agent being chosen from isopropyl myristate, isopropyl palmitate, isononyl isononanoate , neopentyl glycol dioctanoate, branched parafines, organofunctional silicones or a silicone oil consisting of a cyclic chain of 4, 5, 6 or 7 D siloxyl units of formula:
• R 2 SiO 2 Z 2 in which the symbols R, which are identical or different, each represent a linear or branched C 1 -C 6 alkyl radical, preferably methyl, or an aryl or alkylaryl radical having from 6 to 8 atoms carbon, preferably phenyl.
• organofunctional silicone is meant a silicone oil, preferably polydimethylsiloxane, some of whose silicon atoms carry organic groups (instead of methyl groups in the case of a polydimethylsiloxane) such as polyethers, paraffins, esters, alcohols, etc. the distribution of these groups may be random or statistical or correspond to a block copolymer or comb structure. For example, copolyols of the comb copolymer or polydimethylsiloxane-polyether block type may be mentioned. These organofunctional silicones are those which are soluble in the silicone material.
• the compatibilizing agent plays various roles and has certain properties.
• the solubilized active molecule concentration plays an essential role in controlling the kinetics of release of this active molecule.
• the agent compatibilization is miscible with the silicone components of the silicone material, to allow optimal dispersion of the entire incorporated amount of active ingredient in the material. It does not interfere with the crosslinking reaction which is at the origin of the formation of the material. Nevertheless, after cross-linking of the material, it allows the active molecule to diffuse through and out of the material, and for example to be delivered in contact with the skin, a tissue, a mucous membrane, etc.
• the amount of active molecule incorporated can advantageously exceed the solubilization capacity of the compatibilizing agent, so that the active molecule is present partly in the solubilized state and partly in the dispersed state (liquid dispersion, eg droplets, or solid, eg powder).
• the concentration gradient is established through the material, towards the area in contact with the skin or the like, and, as the solubilized portion is consumed, the so-called dispersed portion is progressively solubilized.
• the dispersed form plays the role of reservoir in active molecule.
• the invention therefore makes it possible to incorporate higher deliverable active molecule contents than in the past, thanks to the use of the compatibilizing agent and, moreover, where appropriate, thanks to the presence of an active molecule reservoir. .
• the maximum concentration will vary depending on the degree of solubility of the active molecule in the material and in particular in the compatibilizer, and depending on the content of this agent.
• the content of compatibilizing agent may be between 5 and 50% by weight, preferably between 10 and 30% by weight, expressed relative to the total composition.
• the concentration of solubilized active material is advantageously at least 1.5 times the maximum concentration that it would be possible to solubilize in the absence of the compatibilizer. It is preferably at least 2 times higher, and more preferably at least 2.5 or 3 times higher.
• the content of compatibilizing agent can be adjusted so that the amount of solubilized active molecule meets this definition.
• the overall content of active molecule and compatibilizing agent must, however, remain within the limits which make it possible to form, by crosslinking, a silicone material having the desired mechanical properties, knowing that, in certain cases, it may be desirable or useful to place the material in a pocket or the like, as described infra. This overall content can be up to 75% by weight of the total composition. More generally, the overall content can be up to 50% by weight.
• the concentration of active molecule solubilized in the silicone material may be greater than or equal to 5% by weight relative to total weight of the material. It is preferably greater than or equal to 10% and even more preferably greater than or equal to 15, 20, 25 or 30% by weight relative to the total weight of the material (in particular up to 35, 40 or 50%).
• the overall content (solubilized and dispersed) active molecule may be between 5 and 60%, preferably between 10 and 40 or 50%, or between 10 and 30% by weight relative to the total weight of the material.
• the active ingredient can be mixed with the compatibilizing agent, and then the mixture can be introduced into the composition forming the silicone material or in one of its silicone constituents.
• the forming composition of the silicone material and the compatibilizing agent are mixed, and then the active molecule is added and mixed.
• the material can incorporate several active molecules.
• the cosmetic active ingredients soluble in the compatibilizing agent may be chosen in particular from antioxidants (radical action), vitamins, moisturizers, amino acids, vegetable oils rich in polyunsaturated fatty acids, phytosterols, unsaponifiables, ceramides, UV filters, plant extracts , ⁇ -hydroxy acids as well as additives such as organic pigments.
• Examples of medicinal active principles that are soluble in the compatibilizing agent that may be incorporated into the material according to the invention include, in particular, antibacterial agents, antimycotic agents, anti-acne agents, sedatives and tranquilizers, anxiolytics, hormones, androgenic steroids, estrogenic steroids, progestational steroids, analgesics, hypoglycemics, antispasmodics, beta blockers, nonsteroidal antinflammatories, antiosteoporotic agents, skin whiteners, vasodilators, antihypertensives, antiparkinsonians, anti-migraine, anti-cancer drugs and nutritional intakes such as vitamins, essential amino acids, and essential fatty acids. Dermatological applications are particularly sought after.
• Mention may also be made of compounds having a favorable action in the field of personal care or personal hygiene, for example a refreshing and / or deodorizing or deodorant action, such as menthol and methyl diisopropyl propionamide (WS-23 ® ) provided by Rhodia.
• a refreshing and / or deodorizing or deodorant action such as menthol and methyl diisopropyl propionamide (WS-23 ® ) provided by Rhodia.
• the silicone material may be a gel or an elastomer.
• This material is obtained by hydrosilylation reaction (polyaddition) between a polyorganosiloxane carrying alkenylsiloxy units and a polyorganosiloxane bearing hydrogenosiloxy units in the presence of a hydrosilylation catalyst.
• Crosslinking can to be carried out cold or at low temperature, generally below 50 0 C, and compatible with maintaining the integrity of the active molecule.
• the silicone materials referred to are conventionally constituted by the product of a hydrosilation reaction occurring in a mixture essentially comprising a polyorganosiloxane carrying alkenyl reactive groups containing from 2 to 6 carbon atoms, preferably vinyl, bonded to silicon, a polyorganosiloxane bearing silicon-bonded hydrogen atoms, and a platinum catalyst.
• the gels are generally characterized by a penetration value ranging from 150 to 350 tenths of a millimeter according to DIN ISO 2137.
• the elastomers of the invention are cold vulcanizable elastomers (RTV) having a Shore A hardness of from about 5 to about 30 and those having a Shore 00 hardness of about 15 to about 40, according to DIN 53505. Such compositions are well known to those skilled in the art.
• gel compositions comprising:
• At least one polyorganosiloxane POS (1) comprising: a) M-type siloxy units terminals of formula: (R) 2 (alkenyl) SiO ⁇
• R 7 (R 7 ) 2 SiO 272 in which R 1, R 2, which are identical to or different from each other, have the same definition as R;
• the ratios of the polyorganosiloxanes POS (I), POS (II) and POS (III) are chosen as is known per se, for obtaining a gel during the crosslinking.
• POS (I) which are more readily used, are ⁇ , ⁇ (dimethylvinylsiloxy) polydimethylsiloxanes.
• POS (I) are commercially available (e.g. RHODORSIL® 620 V from RHODIA).
• POS poly (dimethylsiloxy) (siloxymethylhydrogen) ⁇ , ⁇ (dimethylhydrogensiloxy).
• POS (II) are commercial products such as the
• the extender (III) is a polyorganosiloxane (POS) advantageously having H-Si only on its M terminal siloxyl units. It is preferably of much lower viscosity than the POS (I), for example of the order of that of the POS (II).
• POS (III) The structure and the method of preparation of POS (III) that can be used in the composition of the invention are furthermore largely illustrated by the prior technical literature.
• POS (H1) As an example of a commercial product that may be used as POS (H1), mention may be made of RHODORSIL® 620 H2 from RHODIA.
• This POS (IV) is, for example, constituted by an ⁇ , ⁇ (trimethylsiloxy) polydimethylsiloxane oil. This type of POS is perfectly commercially available, for example the product marketed by RHODIA under the name RHODORSIL® 47 V 100.
• the composition comprises at least one POS (IV) of substantially linear structure and lower dynamic viscosity than that of the POS (I), preferably at least 20 times lower, and more preferably still 5 times less than that of POS (I). It goes without saying that the proportions of alkenyl and H-Si groups present in each of the POS (I) to (III) of the composition are not innocuous. This is a non-limiting illustration:
• POS (II) H-Si present in a proportion of from 0.01 to 10, preferably from 0.1 to 1.5, and still more preferably in a proportion of approximately 0.7% by weight
• POS (III) H-Si present in a proportion of from 0.01 to 10, preferably from 0.05 to 1 and even more preferably, at a level of approximately 0.2% by weight.
• the catalyst (V) is another important element of the composition according to the invention. It is preferably an organometallic platinum complex or else one of the platinum-based catalysts conventionally used for the catalysis of hydrosilylation reactions between SiH residues and SiVi residues.
• the viscosity of the POS of the composition according to the invention also constitutes a parameter to be taken into consideration, particularly with regard to the ease of handling of this composition and the viscoelastic properties of the gel that can be obtained by crosslinking this composition.
• the POS (I) is substantially linear and has a dynamic viscosity of less than or equal to 500,000 m.sup.-3 Pa, preferably between 1000 and 200,000 mPa.
• a composition according to the preferred embodiment of the invention may be that characterized in that:
• the composition of the silicone material may also comprise other ingredients, such as plasticizers and skin transfer accelerators or adsorption promoters, to promote the diffusion of the active ingredient through the skin.
• These products most often belong to the group of fatty acids, fatty acid esters, fatty alcohols, optionally oxyethylenated, fatty derivatives of propylene glycol, fatty derivatives of ethylene glycol, fatty derivatives of terpenes. Mention may also be made of ethylene glycol monoethyl ether (eg Transcutol®), which is a well-known diffusion promoter.
• the present invention also relates to any object incorporating or consisting of the material according to the invention.
• This object may be a patch, preferably adhesive, intended to be placed in contact with the skin or a tissue, for cosmetic (cosmetic molecule) or pharmaceutical (biologically or pharmaceutically active molecule, particularly in dermatology) applications.
• the patch comprises the material according to the invention, comprising the active molecule, placed on a support allowing the application.
• the material may be present in the form of a film of a few tenths of millimeters deposited on a support and possibly protected by a protective film pelliculo ⁇ dal.
• This object may also be a pocket or the like containing the material, formed of a membrane or a film in a resistant material but through which the active molecule can pass, diffuse.
• the membrane or film may for example be made of polyurethane.
• the material according to the invention can be used as an insert, possibly a cushion, in a shoe, a toggle, an article of clothing, sportswear or body protection, and more generally in any object intended to be carried by a living being, in particular a human, in a location in direct or indirect contact with a part of the body, while having the special properties related to the diffusion of the active molecule, essentially of the molecule type for personal or cosmetic care, eg menthol, antiperspirant, perfume, deodorant or deodorant. Any object of this type, including such an insert is also an object of the invention.
• a woven or non-woven textile article with a material according to the invention, the material being deposited on the textile before crosslinking. It may also be to deposit (e.g. layer ranging from 100 microns to several mm) and fix, by crosslinking, the material on such a textile.
• a textile thus treated, and any article containing it, is an object of the invention.
• the preparation of the material it can be specified that the crosslinking of the composition occurs at room temperature or after heating at temperatures that are not likely to destroy the active molecule and the compatibilizer.
• Menthol is solubilized either in isopropyl myristate or in D5, or in a mixture of these two solvents. These solutions are then introduced into the mixtures of parts A and B of the gels.
• oil 2 oil pdms of viscosity 300 mPa.s at CH 3 SiH and Si (CH 3 ) 2 H; H content ⁇ 0.17% by weight.
• oil 3 oil viscosity of 7 to 10 mPa.s at Si (CH 3 ) 2 H groups located at the ends of chains; H content ⁇ 0.19% by weight.
• Menthol solutions are prepared by dissolving the menthol crystals in D5 or I 1 IPM 30-50 0 C. After dissolution, the solutions are brought to room temperature; at this point, if necessary, the second solvent is added.
• Table-2 Reference and Composition of Menthol Solutions; in% by weight
• the mixtures of the various constituents which are used to prepare the patches are obtained at ambient temperature in the following way: the parts A & B of each of the gel formulations are mixed by manual mixing using a spatula at a rate of 1 part of A for 1 part of B; the different amounts of solutions and solvents are weighed, then introduced always by manual mixing in the previous mixtures; - The mixtures are then degassed so as to eliminate the air bubbles that were introduced at the time of preparation of the mixtures. Degassing is performed by light vacuum treatment.
• the mixtures are poured into Petri dishes or polyethylene cans.
• the crosslinking is carried out at ambient temperature for 12 to 24 hours.
• the patches are transparent, they are also self-adhesive on the skin, glass, plastics, and release Menthol, detectable thanks to its specific smell.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Preparation (AREA)
• Compositions Of Macromolecular Compounds (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=34953816

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (8)

Family Cites Families (22)

• 2004
  • 2004-12-24 FR FR0413931A patent/FR2879931B1/fr not_active Expired - Fee Related
• 2005
  • 2005-12-23 BR BRPI0519619-1A patent/BRPI0519619A2/pt not_active IP Right Cessation
  • 2005-12-23 CN CNA2005800477607A patent/CN101166513A/zh active Pending
  • 2005-12-23 KR KR1020077014375A patent/KR20070110486A/ko not_active Abandoned
  • 2005-12-23 JP JP2007547581A patent/JP2008525391A/ja not_active Ceased
  • 2005-12-23 US US11/794,094 patent/US20090124699A1/en not_active Abandoned
  • 2005-12-23 EP EP05850608A patent/EP1833459A2/fr not_active Withdrawn
  • 2005-12-23 WO PCT/FR2005/003271 patent/WO2006070134A2/fr not_active Ceased
• 2012
  • 2012-10-12 JP JP2012227376A patent/JP2013014621A/ja active Pending

Also Published As

Similar Documents

Legal Events